Safety and Efficacy of Convalescent Plasma in COVID-19: An Overview of Systematic Reviews
Open Access
- 11 September 2021
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 11 (9), 1663
- https://doi.org/10.3390/diagnostics11091663
Abstract
Convalescent plasma (CP) from patients recovered from COVID-19 is one of the most studied anti-viral therapies against SARS-COV-2 infection. The aim of this study is to summarize the evidence from the available systematic reviews on the efficacy and safety of CP in COVID-19 through an overview of the published systematic reviews (SRs). A systematic literature search was conducted up to August 2021 in Embase, PubMed, Web of Science, Cochrane and Medrxiv databases to identify systematic reviews focusing on CP use in COVID-19. Two review authors independently evaluated reviews for inclusion, extracted data and assessed quality of evidence using AMSTAR (A Measurement Tool to Assess Reviews) and GRADE tools. The following outcomes were analyzed: mortality, viral clearance, clinical improvement, length of hospital stay, adverse reactions. In addition, where possible, subgroup analyses were performed according to study design (e.g., RCTs vs. non-RCTs), CP neutralizing antibody titer and timing of administration, and disease severity. The methodological quality of included studies was assessed using the checklist for systematic reviews AMSTAR-2 and the GRADE assessment. Overall, 29 SRs met the inclusion criteria based on 53 unique primary studies (17 RCT and 36 non-RCT). Limitations to the methodological quality of reviews most commonly related to absence of a protocol (11/29) and funding sources of primary studies (27/29). Of the 89 analyses on which GRADE judgements were made, effect estimates were judged to be of high/moderate certainty in four analyses, moderate in 38, low in 38, very low in nine. Despite the variability in the certainty of the evidence, mostly related to the risk of bias and inconsistency, the results of this umbrella review highlight a mortality reduction in CP over standard therapy when administered early and at high titer, without increased adverse reactions.This publication has 75 references indexed in Scilit:
- Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a rapid reviewEmergencias, 2020
- “Hydroxychloroquine in patients with COVID-19: A Systematic Review and meta-analysis.”Diabetes & Metabolic Syndrome: Clinical Research & Reviews, 2020
- Convalescent plasma transfusion for the treatment of COVID‐19: Systematic reviewJournal of Medical Virology, 2020
- Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trialThe Lancet, 2020
- The possible of immunotherapy for COVID-19: A systematic reviewInternational Immunopharmacology, 2020
- Real estimates of mortality following COVID-19 infectionThe Lancet Infectious Diseases, 2020
- AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or bothBMJ, 2017
- Randomized controlled trials vs. observational studies: why not just live together?BMC Anesthesiology, 2016
- Regional anesthesia and lipid resuscitation for local anesthetic systemic toxicity in China: results of a survey by the orthopedic anesthesia group of the chinese society of anesthesiologyBMC Anesthesiology, 2015
- Comparison of Evidence of Treatment Effects in Randomized and Nonrandomized StudiesJAMA, 2001